Knop FK - Search Results

1

Signs of Glucagon Resistance After a 2-Week Hypercaloric Diet Intervention.

Suppli MP, Høgedal A, Bagger JI, Chabanova E, van Hall G, Forman JL, Christensen MB, Albrechtsen NJW, Holst JJ, Knop FK. Suppli MP, et al. Among authors: knop fk. J Clin Endocrinol Metab. 2024 Mar 15;109(4):955-967. doi: 10.1210/clinem/dgad666. J Clin Endocrinol Metab. 2024. PMID: 37967235

2

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.

Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Diabetes Care. 2003 Sep;26(9):2581-7. doi: 10.2337/diacare.26.9.2581. Diabetes Care. 2003. PMID: 12941722 Clinical Trial.

3

The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ. Vilsbøll T, et al. Among authors: knop fk. J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903. doi: 10.1210/jc.2003-030738. J Clin Endocrinol Metab. 2003. PMID: 14557471 Clinical Trial.

4

Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution.

Knop FK, Vilsbøll T, Larsen S, Højberg PV, Vølund A, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E324-30. doi: 10.1152/ajpendo.00059.2006. Epub 2006 Sep 5. Am J Physiol Endocrinol Metab. 2007. PMID: 16954337 Free article. Clinical Trial.

5

Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Diabetologia. 2007 Apr;50(4):797-805. doi: 10.1007/s00125-006-0566-z. Epub 2007 Jan 16. Diabetologia. 2007. PMID: 17225124

6

Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?

Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T. Knop FK, et al. Diabetes. 2007 Aug;56(8):1951-9. doi: 10.2337/db07-0100. Epub 2007 May 18. Diabetes. 2007. PMID: 17513701

7

The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.

Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Regul Pept. 2007 Dec 4;144(1-3):123-30. doi: 10.1016/j.regpep.2007.07.002. Epub 2007 Jul 13. Regul Pept. 2007. PMID: 17692937

8

Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility.

Knop FK, Holst JJ, Vilsbøll T. Knop FK, et al. IDrugs. 2008 Jul;11(7):497-501. IDrugs. 2008. PMID: 18600596 Review.

9

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Aaboe K, Knop FK, Vilsboll T, Vølund A, Simonsen U, Deacon CF, Madsbad S, Holst JJ, Krarup T. Aaboe K, et al. Among authors: knop fk. J Clin Endocrinol Metab. 2009 Feb;94(2):603-8. doi: 10.1210/jc.2008-1731. Epub 2008 Dec 2. J Clin Endocrinol Metab. 2009. PMID: 19050053 Clinical Trial.

10

Incretin-based therapy of type 2 diabetes mellitus.

Knop FK, Vilsbøll T, Holst JJ. Knop FK, et al. Curr Protein Pept Sci. 2009 Feb;10(1):46-55. doi: 10.2174/138920309787315158. Curr Protein Pept Sci. 2009. PMID: 19275672 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

506 results

Search Page